These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37450849)

  • 1. Pharmaceutical Industry Perspective on the Non-Clinical Evaluation of Novel Excipients: Results From an Industry Survey Conducted by the IQ Novel Excipient Working Group.
    Giffen PS; Buckley LA; Pinkstaff J
    Int J Toxicol; 2023 Dec; 42(6):480-488. PubMed ID: 37450849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical excipient development: the need for preclinical guidance.
    Baldrick P
    Regul Toxicol Pharmacol; 2000 Oct; 32(2):210-8. PubMed ID: 11067777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Technical system, strategy and development trend of excipient innovation research for pediatric preparations].
    Su XY; Yang YJ; Zhu MM; Jia XB; Feng L
    Zhongguo Zhong Yao Za Zhi; 2022 Nov; 47(21):5700-5707. PubMed ID: 36471988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity of excipients--a Food and Drug Administration perspective.
    Osterberg RE; See NA
    Int J Toxicol; 2003; 22(5):377-80. PubMed ID: 14555410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision Support for Excipient Risk Assessment in Pharmaceutical Manufacturing.
    Bejarano A; Hewa Nadungodage C; Wang F; Catlin AC; Hoag SW
    AAPS PharmSciTech; 2019 Jun; 20(6):223. PubMed ID: 31214878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vendor qualification for pharmaceutical excipients--GMP requirements and approach.
    Patel KT; Chotal NP
    Pharmazie; 2010 Nov; 65(11):783-90. PubMed ID: 21155382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Pharmaceutical Excipients Threaten the Aquatic Environment? A Risk Assessment Based on the Microtox
    Turek M; Różycka-Sokołowska E; Koprowski M; Marciniak B; Bałczewski P
    Molecules; 2023 Sep; 28(18):. PubMed ID: 37764366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excipient variability and its impact on dosage form functionality.
    Dave VS; Saoji SD; Raut NA; Haware RV
    J Pharm Sci; 2015 Mar; 104(3):906-15. PubMed ID: 25561249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comprehensive Scientific Survey of Excipients Used in Currently Marketed, Therapeutic Biological Drug Products.
    Rao VA; Kim JJ; Patel DS; Rains K; Estoll CR
    Pharm Res; 2020 Sep; 37(10):200. PubMed ID: 32968854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Overview of Pharmaceutical Excipients: Safe or Not Safe?
    Abrantes CG; Duarte D; Reis CP
    J Pharm Sci; 2016 Jul; 105(7):2019-26. PubMed ID: 27262205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution and challenges for the international harmonization of the regulation of pharmaceutical excipients in Taiwan.
    Chang LC; Kang JJ; Gau CS
    Regul Toxicol Pharmacol; 2015 Dec; 73(3):947-52. PubMed ID: 26387930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Japan-Specific Key Regulatory Aspects for Development of New Biopharmaceutical Drug Products.
    Desai KG; Obayashi H; Colandene JD; Nesta DP
    J Pharm Sci; 2018 Jul; 107(7):1773-1786. PubMed ID: 29601839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment.
    Boetzel R; Ceszlak A; Day C; Drumm P; Gil Bejar J; Glennon J; Harris L; Heghes CI; Horga R; Jacobs PL; Keurentjes WJTM; King F; Lee CW; Lewen N; Marchant CA; Maris FA; Nye W; Powell S; Rockstroh H; Rutter L; Schweitzer M; Shannon E; Smallshaw L; Teasdale A; Thompson S; Wilkinson D
    J Pharm Sci; 2018 Sep; 107(9):2335-2340. PubMed ID: 29679706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive review on pharmaceutical excipients.
    Pockle RD; Masareddy RS; Patil AS; Patil PD
    Ther Deliv; 2023 Jul; 14(7):443-458. PubMed ID: 37464784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaphylaxis to Excipients in Current Clinical Practice: Evaluation and Management.
    Bruusgaard-Mouritsen MA; Nasser S; Garvey LH; Krantz MS; Stone CA
    Immunol Allergy Clin North Am; 2022 May; 42(2):239-267. PubMed ID: 35469617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excipient pharmacokinetics and profiling.
    Loftsson T
    Int J Pharm; 2015 Mar; 480(1-2):48-54. PubMed ID: 25596414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopharmaceutical aspects and implications of excipient variability in drug product performance.
    Zarmpi P; Flanagan T; Meehan E; Mann J; Fotaki N
    Eur J Pharm Biopharm; 2017 Feb; 111():1-15. PubMed ID: 27845182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the microbiological quality of pharmaceutical excipients.
    Cundell AM
    PDA J Pharm Sci Technol; 2005; 59(6):381-95. PubMed ID: 16471425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
    Boetzel R; Schlingemann J; Hickert S; Korn C; Kocks G; Luck B; Blom G; Harrison M; François M; Allain L; Wu Y; Bousraf Y
    J Pharm Sci; 2023 Jun; 112(6):1615-1624. PubMed ID: 35500671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Overview of Recent Patents and Patented Technology Platforms Based on Co-Processed Excipients.
    Kaushik D; Goel E; Verma R; Pandey P; Purohit D; Mittal V; Kumar K; Rahman MH
    Recent Adv Drug Deliv Formul; 2021; 15(1):3-14. PubMed ID: 33397276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.